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Abstract
Background: As critical mediators of local and systemic inflammatory responses, cytokines are produced
in the brain following ischaemic stroke. Some have been detected in the circulation of stroke patients, but
their role and source is unclear. Focusing primarily on interleukin(IL)-1-related mechanisms, we serially
measured plasma inflammatory markers, and the production of cytokines by whole blood, from 36 patients
recruited within 12 h and followed up to 1 year after acute ischaemic stroke (AIS).
Results: Admission plasma IL-1 receptor antagonist (IL-1ra) concentration was elevated, relative to age-
, sex-, and atherosclerosis-matched controls. IL-1β, soluble IL-1 receptor type II, tumour necrosis factor
(TNF)-α, TNF-RII, IL-10 and leptin concentrations did not significantly differ from controls, but peak
soluble TNF receptor type I (sTNF-RI) in the first week correlated strongly with computed tomography
infarct volume at 5–7 days, mRS and BI at 3 and 12 months. Neopterin was raised in patients at 5–7 d,
relative to controls, and in subjects with significant atherosclerosis. Spontaneous IL-1β, TNF-α and IL-6
gene and protein expression by blood cells was minimal, and induction of these cytokines by
lipopolysaccharide (LPS) was significantly lower in patients than in controls during the first week. Minimum
LPS-induced cytokine production correlated strongly with mRS and BI, and also with plasma cortisol.
Conclusion: Absence of spontaneous whole blood gene activation or cytokine production suggests that
peripheral blood cells are not the source of cytokines measured in plasma after AIS. Increased plasma IL-
1ra within 12 h of AIS onset, the relationship between sTNF-RI and stroke severity, and suppressed
cytokine induction suggests early activation of endogenous immunosuppressive mechanisms after AIS.
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Accumulating evidence supports a role for inflammation
in the development of, and responses to, cerebral ischae-
mia. Cytokines such as interleukin(IL)-1, tumour necrosis
factor-α (TNF-α) and IL-6 appear to be crucial mediators
of such responses [1,2], yet much remains unknown
about their complex interactions in the setting of clinical
stroke.
Although cytokines are detected in the brain and cerebro-
spinal fluid (CSF) of patients with acute ischaemic stroke
(AIS) [3-5], the relevance of measurements in the periph-
eral circulation is uncertain. In a recent prospective study
of ischaemic stroke patients, recruited early (within 12 h)
after onset of symptoms, we reported early induction of
established markers of inflammation, including inter-
leukin-6 (IL-6), and strong relationships between these
and both stroke severity and outcome [6,7]. Despite evi-
dence that IL-1 is an important mediator in stroke, it has
generally not been detected [3,8], other than in one small
study where a very modest elevation was noted in compar-
ison to healthy subjects [9]. However, elevated inter-
leukin-1 receptor antagonist (IL-1ra) concentration has
been reported [10,11], and elevations have been observed
in circulating TNF-α [12-14] and IL-10 [15,16].
It seems reasonable to propose that the increased plasma
cytokines, detected following AIS, originate from inflam-
matory tissue in the central nervous system (CNS), but
this is difficult to prove formally, and it is possible that
they originate peripherally, perhaps from leukocytes that
are activated to enter the circulation in increased num-
bers. Increased IL-1β messenger ribonucleic acid (mRNA)
expression in blood cells, following AIS has been corre-
lated moderately with the degree of neurological impair-
ment [17], although other studies suggest IL-1β protein
production by peripheral blood cells is no different from
controls [18]. There is also evidence that release of TNF-α,
IL-6 and IL-8 by blood cells in response to lipopolysaccha-
ride (LPS) may be increased in patients following AIS, rel-
ative to controls [18,19], suggesting that leukocytes of
patients with AIS may be primed to release cytokines in
response to a secondary stimulus.
In view of these issues we sought to further determine the
relationship between inflammation and AIS, as well as to
identify whether blood leukocytes might be the source of
plasma cytokines. We therefore set out primarily to exam-
ine (a) whether circulating IL-1ra is elevated and related to
stroke severity or outcome, and (b) whether peripheral
blood IL-1β production by peripheral blood leukocytes is
induced or primed, early after AIS. We additionally report
data for related cytokines and inflammatory mediators, in
the same context.
Methods
Patients, control subjects, radiology and assessment of 
atherosclerosis
The study was approved by the Local Research Ethics
Committee and methodology for clinical evaluation was
as described previously [6]. Briefly, patients over 18 years
presenting at Hope Hospital, Salford, within 12 h of
symptom onset of AIS, were eligible. Patients were
excluded if there was any improvement in symptoms
since onset, the time of onset of symptoms could not be
reliably determined, or there was evidence of active malig-
nancy. Control subjects with no history of stroke or tran-
sient ischaemic attack, without clinically evident infection
necessitating medical treatment, and without a history of
cognitive impairment sufficient to interfere with daily life
were matched for age (± 5 years), sex and degree of athero-
sclerosis. Written informed consent (or assent from a rel-
ative) was obtained for all patients and control subjects.
Computed tomography (CT) brain scans were performed
on an IGE CT Pace Plus 3rd generation CT scanner within
24 h of admission, in order to exclude patients with pri-
mary intracerebral haemorrhage or stroke mimic from fur-
ther analysis. Ischaemic stroke patients underwent a
second CT brain scan at 5 to 7 days for determination of
cerebral infarct volume, using a semi-automated tech-
nique [20]. Ankle brachial pressure index (ABPI) was used
to classify degree of atherosclerosis where carotid duplex
data were unavailable. Patients and control subjects were
divided into two groups, one without significant athero-
sclerosis (< 50% carotid artery stenosis bilaterally, or low-
est ABPI ≥ 0.92), and one with significant atherosclerosis
(≥ 50% carotid artery stenosis on at least one side, or low-
est ABPI < 0.92).
Blood and urine samples
Venous blood samples were taken from patients at base-
line, the next 09:00 time point where admission was
before 07:00 or after 11:00, and 24 hours after admission,
plus 5 to 7 days, 3 months and 12 months at 09:00. Blood
was also drawn from resting control subjects at 09:00 and
at a time matched to the patient's time of admission if this
was before 07:00 or after 11:00. Blood was collected into
tubes containing pyrogen-free heparin, and wrapped in
cool-gel packs. At 1 hour after collection, blood was cen-
trifuged at 2000 g for 30 minutes, at 4°C. Plasma was sep-
arated, frozen and stored at -70°C until analysis. Cell
pellets from 10 ml of centrifuged blood were resuspended
in 5 ml saline and 1 ml volumes were centrifuged at
12000 g prior to removing the supernatant and freezing at
-70°C for analysis of cytokine mRNA. Urine was collected
at the same time points into foil-wrapped sterile contain-
ers, wrapped in cool-gel packs, frozen and stored at -70°C
until analysis.Page 2 of 12
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Lipopolysaccharide (LPS) stimulation of whole blood was
performed to assess the potential of peripheral blood leu-
kocytes to produce cytokines after stroke. A separate por-
tion of whole blood was mixed with an equal volume of
Roswell Park Memorial Institute medium (RPMI; Invitro-
gen, Paisley, UK) or RPMI containing LPS (from E. Coli
serotype 0128:B12, Sigma, Gillingham, UK) at 200 ng/ml
and incubated in triplicate 1 ml volumes in 12-well multi-
dishes (Nalge Nunc Int. Roskilde, Denmark). After 24
hours at 37°C in a 5% CO2 atmosphere the contents of
each well were transferred to microcentrifuge tubes and
centrifuged at 12000 g for 10 mins. The supernatant was
separated, frozen and stored at -70°C until analysis.
Enzyme-linked immunosorbent assays
Plasma (or blood culture supernatant) IL-1β, sIL-1-RII,
TNF-α, sTNF-RI, sTNF-RII, IL-10 and leptin were meas-
ured using sandwich enzyme-linked immunosorbent
assays (ELISAs). Analytes were captured on 96-well micro-
plates (Costar, Cambridge, MA) with analyte-specific
monoclonal antibodies (IL-1β : cat no. MAB601, R&D
Systems Europe Ltd., Abingdon, UK, sIL-1-RII: cat no.
MAB663; R&D Systems, TNF-α : supplied by S. Poole,
NIBSC, sTNF-RI: cat no. MAB625; R&D Systems, sTNF-RII:
cat no. 58.177.08; Biosource, Nivelles, Belgium, leptin:
cat no. MAB398; R&D Systems, IL-10: cat no. 58.132.08;
Biosource). IL-1β was secondarily bound with a goat anti-
human antibody (cat no. AF201NA; R&D Systems) fol-
lowed by HRP-conjugated donkey anti-goat antibody
(code number 705-035-147; Jackson ImmunoResearch
Laboratories Inc., PA, USA), prior to development with
orthophenylene-diamine (OPD; Sigma, Poole, UK).
Other analytes were secondarily bound with biotinylated
antibodies (sIL-1-RII: cat no. BAF263; R&D Systems, TNF-
α : supplied by S. Poole (NIBSC, South Mimms, UK);
sTNF-RI: cat no. BAF225, R&D Systems, sTNF-RII: cat no.
58.177.02; Biosource, leptin: cat no. BAM398; R&D Sys-
tems, IL-10: cat no. 58.132.02; Biosource) followed by
streptavidin-HRP (cat no. 43–4323; Zymed Laboratories
Inc., CA, USA, or cat no. 41.000.04; Biosource for the IL-
10 and sTNF-RII assays) and developed with OPD. Work-
ing standards for IL-1β (R&D Systems, cat. no. 2010LB,
TNF-α (supplied by S. Poole, NIBSC), IL-10 (Biosource,
cat no. SD909) were calibrated against WHO interna-
tional standards. Cortisol, IL-6 and IL-1ra were measured
as described previously [6,21]. Other analytes were cali-
brated using commercially available materials: sIL-1-RII:
cat no. 263-2R; R&D Systems; sTNF-RI: cat no. 225-B1;
R&D Systems; sTNF-RII: cat no. 58.177.10; Biosource; lep-
tin: cat no. 398-LP, R&D Systems.
Minimum assay sensitivities, allowing for sample dilution
(1:10 for sIL-RII, sTNF-RI, sTNF-RII and leptin, and 1:5 for
IL-1ra), were 6.5 pg/ml (IL-1β), 352 pg/ml (IL-1ra), 860
pg/ml (sIL-1-RII), 7 pg/ml (TNF-α), 200 pg/ml (sTNF-RI),
1000 pg/ml (sTNF-RII), < 500 pg/ml(leptin), 0.6 pg/ml
(IL-10). Inter-assay coefficients of variation (CVs) for
quality control samples were 15% at 83.5 pg/ml to 26% at
51.5 pg/ml for IL-1β, 11% at 2.48 ng/ml to 19% at 680
pg/ml for IL-1ra, 12% at 1.2 ng/ml to 20% at 145 pg/ml
for sIL-1-RII, 11% at 42 pg/ml to 10 pg/ml for TNF-α), 7%
at 200 pg/ml to 36% at 23 pg/ml for sTNF-RI, 7% at 850
pg/ml to 9% at 300 pg/ml for sTNF-RII), 22% at 67.5 ng/
ml to 28% at 5.4 ng/mlfor leptin, 4% at 235.1 pg/ml to
6% at 8.2 pg/ml for IL-10. For measurements of superna-
tants from unstimulated samples, minimum sensitivities
were 6.7 pg/ml (IL-1β), 3.4 pg/ml (TNF-α) and 7 pg/ml
(IL-6) and interassay CVs were 7% at 56.3 pg/ml to 30%
at 5.9 pg/ml for IL-1β, 11% at 99.5 pg/ml to 19% at 14.5
pg/ml for TNF-α, and 11% at 45 pg/ml, 23% to 45% at 5.3
pg/ml for IL-6. For measurements of supernatants from
LPS-stimulated samples, minimum sensitivities were 7%
for IL-1β, 8.5 pg/ml for TNF-α, 7 pg/ml for IL-6, and 1.6
pg/ml for IL-10. Interassay CVs were 6% at 911 pg/ml to
12% at 19 pg/ml for IL-1β, 10% at 4.6 ng/ml to 19% at 14
pg/ml for TNF-α, 7% at 1.3 ng/ml to 23% at 16.9 pg/ml
for IL-6, and 10% at 261 pg/ml to 16% at 12 pg/ml for IL-
10. Cytokine production was corrected for monocyte
counts obtained at each time point, and adjusted for the
1:1 dilution with RPMI.
Neopterin and creatinine measurement
The urinary neopterin/creatinine ratio was determined by
reverse-phase high performance liquid chromatography
(Spectroflow 400 isocratic pump; Applied Biosystems,
Warrington, UK) at ambient temperature using a 4.6 ×
100 mm analytical column packed with 3 µm particles of
Spherisorb ODS2 (Waters, Milford, MA), preceded by a
4.6 × 10 mm guard cartridge packed with a generic C18
material. Elution was with a gradient of 15 mmol/l potas-
sium phosphate buffer, pH 6.4, at 0.8 ml/min for 6 min
followed by the addition of 6% acetonitrile at 0.8 ml/min
for a further 3 minutes. Neopterin was measured fluori-
metrically (excitation 353 nm, emission 438 nm: LS-5
luminescence spectrophotometer; Perkin-Elmer, Beacons-
field, UK) and the ratio was calculated relative to creati-
nine determined by ultraviolet absorbance at 235 nm
(Spectroflow 757 absorbance detector; Applied Biosys-
tems). Urine samples were diluted 1/10 in 15 mmol/l
potassium phosphate buffer, pH 6.4, containing 0.2% dis-
odium EDTA, prior to injection of 20 µl on to the column.
Urinary neopterin was expressed as a ratio with creatinine
to account for variation in urine volumes. Inter-assay coef-
ficients of variation for urinary neopterin/creatinine were
11.5% at a ratio of 259, 23.4% at 178 and 19.8% at 101.
Measurement of cytokine mRNA in whole blood
RNA was isolated from the frozen blood cell pellets of 20
sequentially admitted patients, and their matched con-Page 3 of 12
(page number not for citation purposes)
BMC Neurology 2007, 7:5 http://www.biomedcentral.com/1471-2377/7/5trols, using TrizolLS RNA isolation solution (Invitrogen
Ltd., Paisley, UK). The RNA concentration was deter-
mined spectrophotometrically at 260 nm. All RNA sam-
ples for IL-1β mRNA measurements were routinely treated
with 0.5 units RQ1 DNase (Promega, UK) per 50 ng total
RNA at 37°C for 30 mins. The IL-1β, IL-6 and TNF-α
mRNA in these samples were measured using an immu-
nometric, reverse transcriptase, polymerase chain reac-
tion, as previously described [22]. Where IL-6 and TNF-α
mRNA values were high, these were also DNase treated to,
although in no case were results substantially reduced by
this treatment. Cytokine mRNA was expressed as mole-
cules of mRNA/monocyte, assuming total RNA recovery
from blood was 100%.
Statistical Analysis
The pre-specified, primary outcome measures were peak
plasma IL-1ra and maximum IL-1β production by whole
blood during the first week after ischaemic stroke com-
pared with CT cerebral infarct volume at 5 to 7 days and
modified Rankin Scale (mRS) at 3 months. Post-hoc eval-
uation of the data resulted in a change in the IL-1β param-
eter to minimum production. Correlations were assessed
using the Spearman Rank correlation coefficient. Paired t-
tests or logistic regression analysis of log-transformed
cytokine, cytokine receptor, leptin, urinary neopterin, or
cytokine production data were used for group compari-
sons where appropriate. The sample size of 36 patient-
control subject pairs had 80% power at the 5% signifi-
cance level to detect a difference of 0.67 standard devia-
tion (SD) in primary analyses between control subjects
and patients. All calculations were performed using SPSS
for Windows (SPSS Inc., Chicago, IL). Secondary analyses
were plasma IL-1β, sIL-1RII, TNFα, sTNF-RI, sTNF-RII, IL-
10, leptin and urinary neopterin, and IL-1β, IL-6 and TNF-
α production (a) at all time points compared with con-
trols, (b) peak in the first week versus CT infarct volume
at 5 to 7 days and clinical outcome at 3 and 12 months.
Secondary analyses are descriptive, to be used for the pur-
pose of hypothesis generation.
Results
Forty-three patients were recruited between April 2000
and January 2001. Six patients with primary intracerebral
haemorrhage and one patient for whom no matched con-
trol could be found, were excluded. The thirty-six remain-
ing patients included in the analysis were recruited at a
median interval of 4.75 h (range 1.5 h to 11.75 h) from
onset of symptoms of AIS. Fourteen patients died by 12
months: certified causes of death were index stroke (8),
recurrent stroke (1), pulmonary embolism (1), left ven-
tricular failure secondary to myocardial infarction (1) and
sepsis (3). Infections and other events associated with an
inflammatory response occurring in the 6-week period
prior to each assessment were as described previously [6].
Participant characteristics are summarised in table 1. No
patients received treatment with intravenous thromboly-
sis.
Plasma cytokines and soluble receptors
The median plasma IL-1ra concentration was significantly
elevated relative to controls at admission (p < 0.001), and
remained elevated until 5–7 days (fig 1). Peak IL-1ra con-
centration in the first week showed modest correlation
with infarct volume (r = 0.45, p = 0.02), but did not cor-
relate significantly with modified Rankin Scale (mRS) at 3
months, or show meaningful correlations with any other
outcome measures. Plasma IL-1β and sIL-1-RII concentra-
tions were similar to controls at all time points (fig 1) and
also did not exhibit meaningful correlations with out-
come. Peak IL-1ra, IL-1β and sIL-1-RII concentrations did
not exhibit any correlations with each other. Plasma
sTNF-RI concentration was elevated at 5–7 days, in
patients without evidence of infection (fig 1). Peak
plasma sTNF-RI concentration in the first week correlated
strongly with infarct volume (r = 0.62, p = 0.001), mRS at
3 months (r = 0.59, p < 0.001) and 1 year (r = 0.57, p =
0.001), and Barthel Index (BI) at 3 months (r = -0.58, p =
0.001) and 1 year (r = -0.61, p < 0.001). Plasma TNF-α
and sTNF-RII concentrations followed a similar but less
marked pattern to sTNF-RI (fig 1), and peak plasma TNF-
α, sTNF-RI and sTNF-RII concentrations all showed strong
correlations with each other (TNF-α :sTNF-RI, r = 0.64, p
< 0.001; TNF-α : sTNF-RII, r = 0.77, p < 0.001; sTNF-
RI:sTNF-RII, r = 0.83, p < 0.001). Plasma IL-10 and leptin
concentrations were similar to controls at all time points
(not shown).
Peripheral blood cytokine production and gene expression
Following activation with LPS, the cytokines IL-1β, IL-6
and TNF-α were all strongly induced in whole blood. An
850-fold increase was seen in IL-6 production at admis-
sion compared with blood incubated in medium. How-
ever, IL-1β production in blood from patients was
significantly reduced relative to controls between admis-
sion and 5–7 days, and a similar pattern was apparent for
TNF-α and IL-6 (fig 2). This pattern was seen in blood
from all patients, although it was less evident in those
without infection. IL-10 production, measured at admis-
sion and 24 hours after admission, exhibited a similar pat-
tern to IL-1β, TNF-α and IL-6 production at these
timepoints (not shown). Minimum in vitro IL-1β produc-
tion in the first week correlated significantly with mRS at
3 months (table 2). A similar correlation was apparent
between IL-6 production and mRS, although the correla-
tion between TNF production and mRS was less strong
(table 2). Minimum in vitro IL-1β production was lower in
non-survivors than in survivors at 12 months (p = 0.004)
(figure 3), and the same was apparent for IL-6 (p = 0.002)
(figure 3) and TNF-α (p = 0.014) (figure 3). Plasma corti-Page 4 of 12
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LPS-stimulated IL-1β, IL-6 and TNF-α production
between admission and 5–7 days (table 3). In the absence
of LPS, blood incubated in medium for 24 h produced
minimal amounts of IL-1β (Interquartile range (IQR) for
all time points of 22 to 47 pg/106 monocytes (controls),
19 to 66 pg/106 monocytes (patients)), IL-6 (IQR for all
time points 28 to 55 pg/106 monocytes (controls), 28 to
102 pg/106 monocytes (patients)) or TNF-α (IQR for all
time points 39 to 82 pg/106 monocytes (controls), 35 to
90 pg/106 monocytes (patients)). Minimal spontaneous
activation of peripheral blood cells was confirmed by the
absence of cytokine mRNA expression in a group of 20
consecutive patients examined either at admission or 24 h
later (data not shown).
Urinary neopterin
Urinary neopterin was raised in patients at 5–7 days
(median 354 µmol/mol creatinine) compared to controls
(median 254 µmol/mol creatinine) (p = 0.002), but not at
any other time point and a similar elevation was apparent
in patients with evidence of infection excluded. Peak uri-
nary neopterin correlated strongly with peak TNF-α con-
centration (r = 0.6, p < 0.001), but less with sTNF-RI (r =
0.4, p = 0.05) and sTNF-RII (r = 0.4, p = 0.01), and
appeared unrelated to other plasma cytokines, soluble
receptors or in vitro cytokine production.
Atherosclerosis
Seventeen patients and control subjects were classified as
having significant atherosclerosis. A higher urinary neop-
Table 1: Control subject and patient characteristics
Baseline characteristics Controls Patients
Mean age ± S.D. (years) 68.7 ± 12.6 69.6 ± 13.0
Male 24 (67%) 24 (67%) Stroke characteristics
Caucasian 36 (100%) 36 (100%) Oxfordshire Community Stroke Project (OCSP) classification
Systolic blood pressure* 142 (100, 200) 151 (60, 232) Total anterior circulation syndrome 16 (46%)
Diastolic blood pressure* 79 (60, 120) 82 (40, 146) Partial anterior circulation syndrome 12 (34%)
Body mass index* (kg/m2) 26 (17, 36) 26 (18,41) Lacunar syndrome 5 (14%)
'Significant' atherosclerosis 17 (47%) 17 (47%) Posterior circulation syndrome 2 (6%)
Current or former smoker 23 (64%) 25 (69%) National Institutes of Health Stroke Scale (NIHSS) score*
Smoking history unknown 0 (0%) 1 (3%) Admission 14 (3, 24)
Hypertension 11 (31%) 23 (64%) 5–7 days 11 (1, 42)
Atrial fibrillation 2 (6%) 8 (22%) Modified Rankin Scale*
Diabetes mellitus 6 (17%) 3 (8%) Pre-stroke 0 (0, 4)
Ischaemic heart disease 7 (19%) 8 (22%) Barthel Index*
Prevalence of selected drugs** Pre-stroke 100 (20, 100)
Paracetamol Not known 20 (56%)
Statins 11 (31%) 20 (56%)
Antiplatelet agents 14 (39%) 33 (92%) Infections/other events associated with an inflammatory response||
Warfarin 2 (6%) 4 (11%) Pre-stroke 3 (8%)¶
ACEIs† or A-IIR‡ antagonists 5 (14%) 10 (28%) Pre-stroke or 1st week after stroke 11 (33%)¶
NSAIDs§ 4 (11%) 7 (19%)
Beta-blockers 7 (19%) 15 (42%) Pre-3 months 5 (21%)¶
Inhaled corticosteroids 2 (6%) 6 (17%) Pre-1 year 3 (17%)¶
Azathioprine 1 (3%) 0 (0%)
* data shown as median (min, max)
** at recruitment for control subjects; during study period for patients
† angiotensin-converting enzyme inhibitors
‡ angiotensin-II receptor
§non-steroidal anti-inflammatory drugs
|| in 6 weeks prior to assessment
¶number of patients (% of survivors) with infection at each time pointPage 5 of 12
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Plasma cytokine kinetics in all patients and patients without infection (in the 6 weeks preceding assessment)Figure 1
Plasma cytokine kinetics in all patients and patients without infection (in the 6 weeks preceding assessment). Patient values are 
expressed as multiples (ratios) of their corresponding controls (with 95% CIs) to account for skewed distributions. The 24 h 
time point includes "next 9 am" data where admission was between 07:00 and 11:00. *p ≤ 0.01 **p ≤ 0.001 (relative to con-
trols).
BMC Neurology 2007, 7:5 http://www.biomedcentral.com/1471-2377/7/5terin concentration was seen in control subjects with sig-
nificant atherosclerosis (median 309 µmol/mol
creatinine) than those without (median 244 µmol/mol
creatinine) (p < 0.01). IL-10 concentration was lower in
control subjects with significant atherosclerosis (median
0.60 pg/ml) than those without (median 1.00 pg/ml) (p
= 0.05). No notable differences in other plasma cytokines,
soluble receptors or in vitro cytokine production were seen
between those individuals (including patients and con-
trols) with or without significant atherosclerosis at any
time-point.
Discussion
Cytokines such as IL-1, TNF and IL-6 are key regulators of
inflammation at sites of infection or tissue damage. Fol-
lowing AIS, it seems reasonable to hypothesise that
cytokines measured in the plasma arise from cells associ-
ated with inflammatory activity in the brain, but this is
not certain. Therefore, in addition to evaluating the rela-
tionships between plasma cytokines and the clinical
impact of stroke, we have attempted to identify the possi-
ble contribution of peripheral blood leukocytes to the
plasma cytokine pool. We also wanted to know whether
leukocyte activation, apparent in terms of increased num-
bers in the circulation [6], was associated with an
increased potential to produce cytokines. In this study our
primary focus has been the IL-1 system, but we also exam-
ined other cytokines, their receptors, and neopterin, as
molecules that have previously been associated with
inflammatory cell activation.
In accord with its localised role, and with previous studies
[3,8], there was no evidence of an increase in plasma IL-
1β concentration. We also found no change in plasma sIL-
1-RII concentration. However, the elevation in plasma IL-
1ra concentration, at a much earlier stage after stroke
onset than previously reported [10], suggests early activa-
tion of anti-inflammatory components directed at regulat-
ing IL-1. Leptin was evaluated because it appears in some
cases to mediate neuroimmune responses dependent on
IL-1 [23] and, although high leptin levels were recently
found to be associated with stroke [24], the present data
support neither a clear change in leptin concentration fol-
lowing stroke, nor any relationship with outcome.
Our findings with respect to TNF-α are consistent with
one previous study [8], but differ from those showing that
plasma or serum TNF-α concentrations after stroke are
increased and correlate with cerebral infarct volume [12-
14]. The role of TNF-α in stroke remains controversial,
and indeed a potentially beneficial role in ischaemic tol-
erance has been suggested [25]. However, we found sTNF-
RI was increased at 5–7 d and the peak concentration in
the first week correlated with infarct volume and outcome
(mRS and BI) at 3 months and 1 year. This is consistent
with earlier observations of elevated sTNF-RI concentra-
tion in stroke patients with nosocomial infection [26]. A
more robust relationship between sTNF-RI and stroke
severity or outcome may reflect a longer half-life of recep-
tors compared to TNF-α. The possibility that TNF-α and
its receptors are activated in concert is supported by the
strong correlations between their peak concentrations and
suggests their release is proportionate to each other. The
fact that we used controls matched for atherosclerosis,
and that elevated serum sTNF-RI and sTNF-RII concentra-
tions are increased in carotid atherosclerosis [27] may
explain why our data are not as clearly differentiated in
respect of TNF-α as those where healthy controls were
used.
Atherosclerosis may also be a confounding factor with IL-
10 analysis, since patient plasma IL-10 concentrations
were similar to those of controls and reduced concentra-
tions of plasma IL-10 have been noted in studies where
plasma of patients with stroke has been compared to that
of healthy controls [15]. In support of this explanation,
higher plasma concentrations of IL-10 have been detected
in plasma of patients with stable, versus unstable coro-
Table 2: Correlation matrix of cytokine production versus stroke severity and outcome
Minimum cytokine production in first week
IL-1β IL-6 TNF-α
r p r p r p
Admission NIHSS -0.45 0.008 -0.48 0.003 -0.36 0.04
5–7 day NIHSS -0.34 0.05 -0.30 0.08 -0.27 0.1
Infarct volume -0.43 0.03 -0.37 0.06 -0.31 0.1
3 month mRS -0.63 < 0.001 -0.58 < 0.001 -0.48 0.005
1 year mRS -0.65 < 0.001 -0.65 < 0.001 -0.55 0.002
3 month BI 0.59 < 0.001 0.57 < 0.001 0.47 0.008
1 year BI 0.62 < 0.001 0.65 < 0.001 0.55 0.002
r values are Rank Spearman correlation coefficientsPage 7 of 12
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Lipopolysaccharide-stimulated cytokine production kinetics in all patients and patients without infection (in the 6 weeks pre-ceding assessment)Figure 2
Lipopolysaccharide-stimulated cytokine production kinetics in all patients and patients without infection (in the 6 weeks pre-
ceding assessment). Box plots show medians, 10th and 90th percentiles and outliers. The 24 hour timepoint includes "next 9 am" 
data where admission was between 07:00 and 11:00. *p ≤ 0.01 **p ≤ 0.001 (relative to controls).
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Minimum LPS-stimulated cytokine production in first week in survivors and non-survivors to 12 monthsFigure 3
Minimum LPS-stimulated cytokine production in first week in survivors and non-survivors to 12 months. P values generated 
from analysis of log-transformed data (logistic regression for comparison of survivors and non-survivors, paired t-test for com-
parisons with controls).
Table 3: Correlation matrix of plasma cortisol concentration versus LPS-stimulated whole blood in vitro cytokine production
IL-1β production IL-6 production TNF production
r p r p r p
Control subjects 09:00 -0.09 0.6 -0.001 1.0 -0.39 0.02
Admission matched† 0.18 0.3 -0.02 0.9 -0.06 0.7
Patients Admission -0.57 < 0.001 -0.59 < 0.001 -0.72 < 0.001
24 hours -0.65 < 0.001 -0.64 < 0.001 -0.67 < 0.001
5–7 days -0.58 0.001 -0.48 0.006 -0.68 < 0.001
3 months -0.05 0.8 -0.13 0.5 -0.10 0.6
12 months -0.35 0.2 -0.09 0.7 -0.17 0.5
r values are Rank Spearman correlation coefficients
†admission matched data includes 09:00 values if admission was between 07:00 and 11:00
BMC Neurology 2007, 7:5 http://www.biomedcentral.com/1471-2377/7/5nary syndromes [28] and, experimentally, IL-10 defi-
ciency results in increased atherosclerosis in
apolipoprotein E-deficient mice [29].
Activation of cells of monocytoid lineage is associated
with increased production of neopterin in plasma or
urine. Although we found urinary neopterin to be
increased following stroke, and this is consistent with a
previous report that found neopterin to be increased dur-
ing the first week after stroke [30] we also found it to be
higher in control subjects with significant atherosclerosis.
The association with atherosclerosis has been reported
previously [31] and it is possible that this influences the
strength of the apparent association. Consistent with this
interpretation, another study reported neopterin as being
higher one year after stroke than at the acute stage, and to
be correlated with age [32].
CSF is arguably more relevant than plasma to events
occurring in the brain. However, lumbar puncture poses a
risk of cerebral herniation and it is difficult to obtain CSF
at repeated time points. Plasma, or serum markers there-
fore have potentially greater practical value and have been
evaluated in most studies. It may be that plasma cytokines
do reflect brain cytokines, particularly after an acute cere-
bral event, but the validity of this has not been well estab-
lished, and blood monocytes in particular are potential
sources of plasma cytokines. This is particularly the case
where serum, rather than plasma, has been collected and
there is potential for monocytes to release cytokines dur-
ing clotting, particularly if endotoxin is present in collec-
tion tubes [33,34]. The ability of blood cells to produce
cytokines is potentially relevant, not only because they
may be responsible for producing the cytokines while in
the circulation but because these cells have the potential
to enter the CNS after stroke and their activation state may
reflect systemic responsiveness of the immune system
after stroke. Our determination of cytokine gene activa-
tion in the blood of patients, and of spontaneous, whole
blood cytokine induction, indicates peripheral blood cells
are not the source of cytokines after ischaemic stroke. This
supports the hypothesis that cytokine production is
upregulated within the brain, possibly by microglia, in
response to cerebral ischaemia, and these cytokines enter
the peripheral circulation via reabsorption from the CSF,
or via afferent lymphatics. While cells in other peripheral
tissues, such as those associated with concomitant periph-
eral atherosclerosis, might also be expected to be contrib-
utors to a pre-existing inflammatory state, it seems
unlikely that they would be more readily activated than
blood cells following a stroke.
In contrast to the increased plasma cytokines, presumed
to originate from the brain, we report, for the first time,
reduction of cytokine production by endotoxin-stimu-
lated whole blood from patients relative to controls. This
was seen within hours of ischaemic stroke and persisted
during the first week. These data differ from a previous
report, where LPS-induced more IL-6 and TNF in blood
from patients with stroke, compared to controls [19].
However, they are consistent with a number of studies
examining cytokine production by whole blood from
trauma patients [35,36]. Reasons for conflict with the ear-
lier study [19] are not clear, although in that study: (1)
cytokines were induced for only 4 h by LPS, which might
be relevant if downregulation is relatively delayed; (2)
data were not corrected for monocyte count; (3) non-nor-
mally distributed data were analysed with parametric sta-
tistical tests and (4) controls were not matched for degree
of atherosclerosis. Suppression of endotoxin-stimulated
cytokine production, and the inverse relationships with
stroke severity and outcome, may relate to the extent of
CNS inflammation and a physiological attempt to down-
regulate cytokine activation, although it should be noted
that the correlation with infarct volume was relatively
weak. The mechanisms are therefore unclear although,
following trauma, a suppressive factor has been shown to
be present in serum and this was apparently not trans-
forming growth factor (TGF)-β, IL-4 or IL-10 [36]. IL-10
seems unlikely to have contributed to the relative reduc-
tion in cytokine production observed in the present study
because its production pattern was similar to those of IL-
1β, IL-6 and TNF-α. It seems unlikely that reduced capac-
ity to produce cytokines is due to depletion in vivo, since
there was no evidence for increased IL-1β or TNF-α in the
plasma, and mRNA for all three cytokines had not been
induced at baseline.
We have previously reported elevation in plasma cortisol
concentration within 12 hours of ischaemic stroke [6] and
the correlation between plasma cortisol and suppression
of cytokine production, suggests this might be a potential
explanation. These observations are consistent with exper-
imental data describing a systemic anti-inflammatory
response, including reduced endotoxin stimulated whole
blood TNF-α and increased IL-10 production, after infu-
sion of IL-1β into the brain, through stimulation of the
hypothalamo-pituitary-adrenal axis and the sympathetic
nervous system [37]. However, evidence from experimen-
tal ischaemia suggests that activation of the sympathetic
nervous system, but not corticosteroid receptors, is more
important in suppression of whole blood TNF production
[38]. Both catecholamines and corticosteroids suppress
endotoxin-induced cytokine production by whole blood
from healthy volunteers [39,40]. Such regulatory
responses, and increases in inhibitory cytokines such as
IL-1ra, may be responsible for increased vulnerability of
stroke patients to infections [38,41,42]. This might con-
tribute toward the increased mortality in patients with
greatest inhibition of systemic cytokine induction.Page 10 of 12
(page number not for citation purposes)
BMC Neurology 2007, 7:5 http://www.biomedcentral.com/1471-2377/7/5Particular strengths of the present study are the very early
recruitment of patients after onset of symptoms of AIS
(median < 5 h), and further assessments within the first
24 h of admission. In studies where later sampling time
points have been used it is difficult to distinguish the
effects of the stroke itself from subsequent infections or
other events. We also recognise that cytokine responses
seen at 3 months and 1 year reflect the fact that many
patients with the most severe strokes did not survive to
later time points. Control subjects were individually
matched for degree of atherosclerosis, in addition to age
and sex, because each of these variables are known to
influence peripheral inflammatory markers, including IL-
6 and neopterin [43]. The rationale for carotid artery ste-
nosis and ABPI thresholds for 'significant atherosclerosis'
used in the present study was guided by the available evi-
dence, as discussed previously [6]. Possible criticisms of
the present study might include our relatively small sam-
ple size and multiple statistical testing. We may have
missed some associations through the former, and may
have identified spurious associations through the latter.
However, we clearly stated the primary questions at the
study outset and believe that we are reporting data that
should provide an important stimulus for further study.
Conclusion
The present data confirm the association between periph-
eral inflammatory markers and stroke and also draw
attention to the potential confounding issue of the associ-
ation between stroke and atherosclerosis. Peripheral
blood cells appear to make no major contribution to the
plasma cytokine concentration after stroke and, compared
to age-, sex-, and atherosclerosis-matched control sub-
jects, are relatively resistant to activation by LPS. This
reduced production of cytokines is significantly correlated
with worse outcome and mortality, and highlights the
potential of identifying vulnerable subjects for treatment.
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